Neurodegenerative disease trials face persistent challenges: long study durations, progressive disability, high participant burden, and limited sensitivity of traditional endpoints. As these complexities grow, so does the need for trial models that better reflect real-world disease progression, without compromising scientific rigor or regulatory expectations.

Digital health technologies (DHTs), from wearables and remote assessments to AI-enabled analytics, are increasingly being integrated into decentralized and hybrid trial designs. Supported by evolving global regulatory frameworks, these tools offer new opportunities to enhance data quality, expand access, and create more patient-centric research models.